ALK announces top-line results from the five-year landmark GRAZAX® Asthma Prevention (GAP) trial in children
January 14, 2016 11:05 ET
|
ALK Abello
Copenhagen, 2016-01-14 17:05 CET (GLOBE NEWSWIRE) --
The trial did not show an effect in terms of time to first diagnosis of reversible impairment of lung function.
The trial...
ALK upgrades its full-year 2015 financial outlook following Q4 sales upturn in Europe
January 06, 2016 11:24 ET
|
ALK Abello
Copenhagen, 2016-01-06 17:24 CET (GLOBE NEWSWIRE) --
ALKB:DC / OMX: ALK B / AKABY / AKBLF: In response to a continuing increasing demand, SLIT-tablet production has already been increased...
ALK opjusterer sine finansielle forventninger til 2015 som følge af salgsudviklingen i Europa i fjerde kvartal
January 06, 2016 11:24 ET
|
ALK Abello
København, 2016-01-06 17:24 CET (GLOBE NEWSWIRE) --
ALKB:DC / OMX: ALK B / AKABY / AKBLF: Som følge af en fortsat stigende efterspørgsel er produktionen af SLIT-tabletter forøget, og ALK...
ALK to Ring The Nasdaq Stock Market Closing Bell
December 30, 2015 10:00 ET
|
Nasdaq, Inc.
ADVISORY, Dec. 30, 2015 (GLOBE NEWSWIRE) -- What: ALK, a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment, will visit the Nasdaq...
ALKs partner, Torii, indsender registreringsansøgning for tabletvaccine mod cedertræsallergi i Japan
December 25, 2015 03:00 ET
|
ALK Abello
København, 2015-12-25 09:00 CET (GLOBE NEWSWIRE) --
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) meddelte i dag, at dets partner, Torii, har indsendt en registreringsansøgning i Japan for...
ALK’s partner, Torii, submits registration application for the cedar SLIT-tablet in Japan
December 25, 2015 03:00 ET
|
ALK Abello
Copenhagen, 2015-12-25 09:00 CET (GLOBE NEWSWIRE) --
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its partner, Torii, has submitted a New Drug Application in Japan for...
ALK divests its European veterinary business
December 21, 2015 03:49 ET
|
ALK Abello
Copenhagen, 2015-12-21 09:49 CET (GLOBE NEWSWIRE) --
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that it has entered into an agreement to divest its European veterinary...
ALK frasælger sin europæiske veterinærforretning
December 21, 2015 03:49 ET
|
ALK Abello
København, 2015-12-21 09:49 CET (GLOBE NEWSWIRE) --
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) meddelte i dag, at selskabet har indgået en aftale om at frasælge sin europæiske...
New product product (ACARIZAX®) for for treatment of house dust mite allergic rhinitis and asthma obtains reimbursement in Denmark
December 09, 2015 05:50 ET
|
ALK Abello
Copenhagen, 2015-12-09 11:50 CET (GLOBE NEWSWIRE) --
Three months ago, ALK's new sublingual allergy immunotherapy tablet for the treatment of allergic rhinitis and allergic asthma was...
New medicine for house dust mite allergic rhinitis now available in Japan
November 25, 2015 20:00 ET
|
ALK Abello
Copenhagen, 2015-11-26 02:00 CET (GLOBE NEWSWIRE) --
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the sublingual allergy immunotherapy product MITICURE™ now will be...